Vigabatrin therapy for refractory complex partial seizures: Review of clinical trial experience in the United States

Acta Neurologica Scandinavica

Volumn 124, Issue SUPPL. 192, 2011, Pages 29-35

  Faught, E ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Clinical trials; Epilepsy; Refractory complex partial seizures; Review; Vigabatrin

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; VIGABATRIN; ANTICONVULSIVE AGENT;

ABDOMINAL PAIN; AGITATION; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; ATAXIA; ATTENTION DISTURBANCE; AUDITORY HALLUCINATION; BACKACHE; BLURRED VISION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); COGNITION; COMPLEX PARTIAL SEIZURE; CONFUSION; CONSTIPATION; COORDINATION; DEPRESSION; DIARRHEA; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; EVOKED AUDITORY RESPONSE; EVOKED SOMATOSENSORY RESPONSE; FATIGUE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GAIT DISORDER; GRANDIOSE DELUSION; HUMAN; HYPERACTIVITY; IRRITABILITY; LARYNX PAIN; LONG TERM CARE; MEMORY DISORDER; MOOD; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; NERVOUSNESS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NYSTAGMUS; PARANOIA; PARESTHESIA; PSYCHOSIS; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SORE THROAT; SPEECH DISORDER; STOMACH IRRITATION; SUICIDE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UNITED KINGDOM; UNITED STATES; UNSTEADINESS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT; XEROSTOMIA; ADULT; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOCAL EPILEPSY; HEADACHE; MALE; REVIEW; SLEEP STAGE;

ADULT; ANTICONVULSANTS; ATAXIA; CLINICAL TRIALS AS TOPIC; DIZZINESS; DRUG ADMINISTRATION SCHEDULE; EPILEPSIES, PARTIAL; FEMALE; HEADACHE; HUMANS; IRRITABLE MOOD; MALE; SLEEP STAGES; UNITED STATES; VIGABATRIN;

EID: 80855131744     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01598.x     Document Type: Article

References (16)

1. Jung MJ, Lippert B, Metcalf BW et al. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. Neurochemistry 1977;29:797-802.
2. Schechter PJ, Tranier Y. Effect of elevated brain GABA concentrations on the actions of bicuculline and picrotoxin in mice. Psychopharmacology (Berl) 1977;54:145-8.
3. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001;90:21-34.
4. Waterhouse EJ, Mims KN, Gowda SN. Treatment of refractory complex partial seizures: role of vigabatrin. Neuropsychiatr Dis Treat 2009;5:505-15.
5. Wilmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009;50:163-73.
6. ®. Tablets [prescribing information]. Deerfield, IL: Lundbeck Inc., 2010.
7. Ben-Menachem E, Sander JW. Vigabatrin therapy for refractory complex partial seizures: review of major European trials. Acta Neurol Scand 2011;124(Suppl. 192):16-28.
8. Browne TR, Mattson RH, Penry JK et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987;37:184-9.
9. French JA, Mosier M, Walker S et al. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:54-61.
10. Dean C, Mosier M, Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999;40:74-82.
11. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-1.
12. Walker SD, Kälviäinen R. Non-vision adverse events with vigabatrin therapy. Acta Neurol Scand 2011;124(Suppl. 192):72-82.
13. Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand 2011;124(Suppl. 192):57-71.
14. Pellock JM. Balancing the clinical benefit of vigabatrin with its associated risk of vision loss. Acta Neurol Scand 2011;124(Suppl. 192):83-91.
15. Browne TR, Mattson RH, Penry JK et al. Multicenter long-term safety and efficacy study of VGB for refractory complex partial seizures: an update. Neurology 1991;41:363-4.
16. Mumford JP, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989;27(Suppl 1):101S-7S.